- The current view of the diagnosis and new treatment options of Cystic Fibrosis2016 | Faculty of Medicine in Pilsen
- Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up2016 | Second Faculty of Medicine
- Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele2019 | Second Faculty of Medicine
- Ivacaftor in adults with cystic fibrosis: a ten-year follow-pu of lung function and nutritional sttus2020 | Second Faculty of Medicine
- Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis2022 | Second Faculty of Medicine
- Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR2015 | Second Faculty of Medicine
- CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials2019 | Second Faculty of Medicine
- Virtual symposium of experts on the occasion of the official launch of the new medicinal product Kaftrio (R) (ivacaftor / tezakaftor / elexacaftor) on the market in the Czech Republic2021 | Second Faculty of Medicine
- Case report of two adults with F508del/3849+10 kb C > T genotype regaining exocrine pancreatic function following treatment with elexacaftor/tezacaftor/ivacaftorPublication without faculty affiliation
- Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study2023 | Second Faculty of Medicine
- Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment2019 | Second Faculty of Medicine
- Therapeutic strategies in cystic fibrosis2014 | Second Faculty of Medicine
- Human epididymis protein 4 (HE4) plasma concentration inversely correlates with the improvement of cystic fibrosis lung disease in p.Phe508del-CFTR homozygous cases treated with the CFTR modulator lumacaftor/ivacaftor combination2023 | Second Faculty of Medicine
- Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)2014 | Second Faculty of Medicine
- GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)2019 | Second Faculty of Medicine
- Causal therapy of cystic fibrosis2014 | Second Faculty of Medicine
- Health-economic aspects of cystic fibrosis screening and therapy2014 | Second Faculty of Medicine
- A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation2011 | Second Faculty of Medicine
- Elexacaftor: next-generation modulator of the CFTR protein2021 | Second Faculty of Medicine
- CFTR protein modulators2019 | Second Faculty of Medicine
- Enhanced Expression of Human Epididymis Protein 4 (HE4) Reflecting Pro-Inflammatory Status Is Regulated by CFTR in Cystic Fibrosis Bronchial Epithelial Cells2021 | Second Faculty of Medicine
- Complex CFTR alleles in the era of CFTR modulator therapy: a case report2023 | Second Faculty of Medicine, Faculty of Medicine in Pilsen, First Faculty of Medicine
- Current possibilities of causal therapy of cystic fibrosis in childhood2021 | Faculty of Medicine in Pilsen